Loading
companiesCompany
Curis
Curis is a United States-based biotechnology company running 2 late-stage cancer trials of Emavusertib in chronic lymphocytic leukaemia and primary CNS lymphoma.
Also called: Curis, Inc.
Overview
Curis, based in Lexington, MA, the United States, is a biotechnology company. Curis is a biotechnology company developing differentiated therapeutics for cancer patients, including an IRAK4 inhibitor in clinical development for haematologic malignancies. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Emavusertib in chronic lymphocytic leukaemia and primary CNS lymphoma. The largest, NCT03328078 (CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)), plans to enrol 152 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Lexington, MA, US
Scorecard
All companies#416of 1244 companies, score 8
- phase 1/2 +1
- modalities +2
- registry trials +5
0 approved, 0 in phase 3, 1 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 2Oral serine/threonine kinase inhibitor
Emavusertib is an oral serine/threonine kinase inhibitor from Curis, Inc., in registered phase 2 trials for chronic lymphocytic leukaemia, brain and spinal cord tumours.
Similar pages
cancers
drugs
Phase 2Oral serine/threonine kinase inhibitor
trials
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)